SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE, for the Fracture Intervention Trial Research Group 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348: 15351541.
  • 2
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ, for the Fracture Intervention Trial Research Group 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA 280: 20772082.
  • 3
    Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC II, Lombardi A, Shad RV, Hirsch LJ, Karpf DB, for the Alendronate Phase III Osteoporosis Treatment Study Group 1995 Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333: 14371496.
  • 4
    Khan SA, Kanis JA, Vasikaran S, Kline WF, Matuszewski BK, McCloskey EV, Beneton MNC, Gertz BJ, Sciberras DG, Holland SD, Orgee J, Coombes GM, Rogers SR, Porras AG 1997 Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 12: 17001707.
  • 5
    Favus M, Emkey R, Leite M, Devogelaer JP, Rodriguez J, Peverly C, Kaur A, Santora A 1997 Five-year treatment of osteoporosis in postmenopausal women with oral alendronate: Effects on bone mass and turnover and safety. J Bone Miner Res 12: S1; S150.
  • 6
    Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes CJ, Wasnich RD, Bone HG, Santora A, Wu M, Desai R, Ross PD, for the Phase III Osteoporosis Treatment Study Group 2000 Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. J Clin Endocrinol Metab 85: 31093115.
  • 7
    Emkey R, Reid I, Mulloy A, Correa-Rotter R, Favus M, Bone H, Gupta J, LaMotta A, Santora A 2002 Ten-year efficacy and safety of alendronate in the treatment of osteoporosis in postmenopausal women. J Bone Miner Res 17: S1; S139.
  • 8
    Black DM, Reiss TF, Nevitt MC, Cauley J, Karpf D, Cummings SR 1993 Design of the Fracture Intervention Trial. Osteoporos Int 3 (Suppl): S29S39.
  • 9
    Garnero P, Delmas PD 1993 Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 77: 10461053.
  • 10
    Rosen HN, Dresner-Pollak R, Moses AC, Rosenblatt M, Zeind AJ, Clemens JD, Greenspan SL 1994 Specificity of urinary excretion of cross-linked N-telopeptides of type I collagen as a marker of bone turnover. Calcif Tissue Int 54: 2629.
  • 11
    De Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tilloison S, Seleznick M, Pinkas H, Wang K 1996 Esophagitis associated with the use of alendronate. N Engl J Med 335: 10161021.
  • 12
    Ensrud KE, Palermo L, Black DM, Cauley J, Jergas M, Orwoll ES, Nevitt MC, Fox KM, Cummings SR 1995 Hip and calcaneal bone loss increase with advancing age: Longitudinal results from the Study of Osteoporotic Fractures. J Bone Miner Res 10: 17781787.
  • 13
    Jones G, Nguyen T, Sambrook P, Kelly PJ, Eisman JA 1994 Progressive loss of bone in the femoral neck in elderly people: Longitudinal findings from the Dubbo osteoporosis epidemiology study. BMJ 309: 691695.
  • 14
    Miller PD, Watts NB, Licata AA, Harris ST, Genant HK, Wasnich RD, Ross PD, Jackson RD, Hoseyni MS, Schoenfeld SL, Valent DJ, Chesnut CH III 1997 Cyclical etidronate in the treatment of postmenopausal osteoporosis: Efficacy and safety after seven years of treatment. Am J Med 103: 468476.
  • 15
    Landman JO, Hamdy NA, Pauwels EK, Papapoulos SE 1995 Skeletal metabolism in patients with osteoporosis after discontinuation of long term treatment with oral pamidronate. J Clin Endocrinol Metab 80: 34653468.
  • 16
    Mortensen L, Charles P, Bekker PJ, Digennaro J, Johnston CC 1998 Risedronate increases bone mass in an early postmenopausal population: Two years of treatment plus one year of follow-up. J Clin Endocrinol Metab 83: 396402.
  • 17
    Burr DB, Forwood MR, Fyhrie DP, Martin RB, Schaffler MB, Turner CH 1997 Bone microdamage and skeletal fragility in osteoporotic and stress fractures. J Bone Miner Res 12: 615.
  • 18
    Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ 2000 Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27: 687694.
  • 19
    Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzl P, Klaushofer K 2001 Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29: 185191.
  • 20
    Balena R, Toolan BC, Shea M, Myers ER, Lee SC, Opas EE, Seedor JG, Klein H, Frankenfield D, Quartuccio H, Fioravanti C, Clair J, Brown E, Hayes WC, Rodan GA 1993 The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 92: 25772586.
  • 21
    Guy JA, Shea M, Peter CP, Morrissey R, Hayes WC 1993 Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties. Calcif Tissue Int 53: 283288.
  • 22
    Lafage MH, Balena R, Battle MA, Shea M, Seedor JG, Klein H, Hayes WC, Rodan GA 1995 Comparison of alendronate and sodium fluoride effects on cancellous and cortical bone in minipigs. J Clin Invest 95: 21272133.
  • 23
    Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB 2001 Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28: 524531.
  • 24
    Christiansen C, Christensen MS, Transbol I 1981 Bone mass in postmenopausal women after withdrawal of oestrogen/gestagen replacement therapy. Lancet 1: 459461.
  • 25
    Lindsay R, Hart DM, Forrest C, Baird C 1980 Prevention of spinal osteoporosis in oophorectomised women. Lancet 2: 11511154.
  • 26
    Greenspan SL, Emkey RD, Bone HG III, Weiss SR, Bell NH, Downs RW Jr, McKeever C, Miller SS, Davidson M, Bolognese MA, Mulloy AL, Heyden N, Wu M, Kaur A, Lombardi A 2002 Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. Ann Intern Med 137: 875883.
  • 27
    McClung M, Wasnich R, Omizo M, Christiansen C, Ravn P, Hosking D, Wu M, Kaur A, Mantz AM, Snodgrass S, Santora A 2002 Resolution of effect following alendronate: Six-year results from the Early Postmenopausal Interventional Cohort (EPIC) study. J Bone Miner Res 17: S1; S134.
  • 28
    Schneider DL, Barrett-Connor EL, Morton DJ 1997 Timing of postmenopausal estrogen for optimal bone mineral density. JAMA 277: 543547.
  • 29
    Cauley JA, Zmuda JM, Ensrud KE, Bauer DC, Ettinger B 2001 Timing of estrogen replacement therapy for optimal osteoporosis prevention. J Clin Endocrinol Metab 86: 57005705.
  • 30
    Nelson HD, Rizzo J, Harris E, Cauley J, Ensrud K, Bauer DC, Orwoll E, for the Study of Osteoporotic Fractures Research Group 2002 Osteoporosis and fractures in postmenopausal women using estrogen. Arch Intern Med 162: 22782284.
  • 31
    Neele SJM, Evertz R, De Valk-De Roo G, Roos JC, Netelenbos JC 2002 Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 30: 599603.
  • 32
    Linder JD, Wilcox CM 2001 Acid peptic disease in the elderly. Gastroenterol Clin North Am 30: 363376.
  • 33
    Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC, Kaur A, Thompson DE, Yates J, Orloff JJ 2000 Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res 12: 112.
  • 34
    Luckey MM, Gilchrist N, Bone HG, Davie MW, de Villiers TJ, Wu M, Daifotis AG, Santora AC, Orloff JJ 2003 Therapeutic equivalence of aledronate 35 milligrams once weekly and 5 milligrams daily in the prevention of postmenopausal osteoporosis. Obstet Gynecol 101: 711721.
  • 35
    Richter JE 2000 Gastroesophageal reflux disease in the older patient: Presentation, treatment, and complications. Am J Gastroenterol 95: 368373.
  • 36
    Faulkner KG 2000 Bone matters: Are density increases necessary to reduce fracture risk? J Bone Miner Res 15: 183187.
  • 37
    Wasnich RD, Miller PD 2000 Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85: 231236.
  • 38
    Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD 2002 Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87: 15861592.
  • 39
    Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112: 281289.